Editas Medicine Inc
$2.55
(as of Jul 3, 11:45 AM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Editas Medicine Inc
Stock Price
$2.55
Ticker Symbol
EDIT
Exchange
NASDAQ
Industry Information for Editas Medicine Inc
Sector
Healthcare
Industry
Biotechnology
Company Description for Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Fundamentals for Editas Medicine Inc
Market Capitalization
$184,168,368
EBITDA
$-200,922,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-3.04
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
83,712,896
Percent Owned by Insiders
0.33%
Percent Owned by Institutions
57.58%
52-Week High
52-Week Low
Technical Indicators for Editas Medicine Inc
Analyst Ratings for Editas Medicine Inc
Strong Buy
4
Buy
1
Hold
8
Sell
2
Strong Sell
0
News About Editas Medicine Inc
Jul 3, 2025, 9:09 AM EST
Editas Medicine, Inc. See more.
Jun 28, 2025, 5:04 AM EST
Investors looking for stocks that can produce dramatic gains in a short amount of time will want to turn their heads toward the biopharmaceutical space. See more.
Jun 17, 2025, 10:29 AM EST
[Illustration of DNA strand with molecular scissors]
See more.
Jun 17, 2025, 10:07 AM EST
Key Points
See more.